Metastatic melanoma in the older patient: Special considerations

Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 Bleyer, 2008, The distinctive biology of cancer in adolescents and young adults, Nat Rev, 8, 288, 10.1038/nrc2349 Jemal, 2010, Cancer Statistics, 2010, CA Cancer J Clin, 60, 277, 10.3322/caac.20073 McAllister, 2010, Tumor-host interactions: a far-reaching relationship, J Clin Oncol, 28, 4022, 10.1200/JCO.2010.28.4257 Simard, 2012, Cancers with increasing incidence trends in the United States: 1999 through 2008, CA Cancer J Clin, 62, 118, 10.3322/caac.20141 Geller, 2002, Strategies for improving melanoma education and screening for men age >or =50 years: findings from the American Academy of Dermatological National Skin Cancer Screening Program, Cancer, 95, 1554, 10.1002/cncr.10855 Cohen, 1987, Malignant melanoma in the elderly, J Clin Oncol, 5, 100, 10.1200/JCO.1987.5.1.100 Averbook, 1998, A long-term analysis of 620 patients with malignant melanoma at a major referral center, Surgery, 124, 746, 10.1067/msy.1998.91269 Chang, 2003, Melanoma in the elderly patient, Arch Surg, 138, 1135, 10.1001/archsurg.138.10.1135 Balch, 2001, prognostic factor analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system, J Clin Oncol, 19, 3622, 10.1200/JCO.2001.19.16.3622 Chao, 2004, Correlation between prognostic factors and increasing age in melanoma, Ann Surg Oncol, 11, 259, 10.1245/ASO.2004.04.015 Azim, 2012, Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling, Clin Cancer Res, 18, 1341, 10.1158/1078-0432.CCR-11-2599 Garavello, 2007, Oral tongue cancer in young patients: a matched analysis, Oral Oncol, 43, 894, 10.1016/j.oraloncology.2006.10.013 Smith, 2009, Extreme aggressiveness and lethality of gastric adenocarcinoma in the very young, Arch Surg, 144, 506, 10.1001/archsurg.2009.77 Brand, 1997, Prolonged survival of 2 years or longer for patients with disseminated melanoma, Cancer, 79, 2345, 10.1002/(SICI)1097-0142(19970615)79:12<2345::AID-CNCR8>3.0.CO;2-K Eton, 1998, Prognostic factors for survival of patients treated systemically for disseminated melanoma, J Clin Oncol, 16, 1103, 10.1200/JCO.1998.16.3.1103 Francken, 2007, Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma, Ann Surg Oncol, 15, 1476, 10.1245/s10434-007-9717-9 Chapman, 1999, Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma, J Clin Oncol, 17, 2745, 10.1200/JCO.1999.17.9.2745 Legha, 1996, Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine, dacarbazine (CVD) and biotherapy using interleukin-2 and interferon alpha, Ann Oncol, 7, 827, 10.1093/oxfordjournals.annonc.a010762 Atzpodien, 2005, Age does not impair the efficacy of immunotherapy in patients with metastatic renal cell carcinoma, Crit Rev Oncol Hematol, 55, 193, 10.1016/j.critrevonc.2005.03.001 Quan, 2005, Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over, Cancer Biother Radiopharm, 20, 11, 10.1089/cbr.2005.20.11 Derhovanessian, 2008, Immunity, ageing and cancer, Immun Ageing, 5, 11, 10.1186/1742-4933-5-11 Lauerova, 2002, Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response, Neoplasma, 49, 159 Hegde, 2011, Metastatic melanoma in the older patient: immunologic insights and treatment outcomes, Expert Rev Pharmacoecon Outcomes Res, 11, 185, 10.1586/erp.11.14 Fridman, 2012, The immune contexure in human tumors: impact on clinical outcome, Nat Rev Cancer, 12, 298, 10.1038/nrc3245 Galon, 2006, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139 Van der Meijden, 2010, Melanomas more serious in the elderly, Ned Tijdschr Geneeskd, 154, A1535 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, 364, 2517, 10.1056/NEJMoa1104621 Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 8, 426 Galon, 2012, The immune score as a new possible approach for the classification of cancer, J Transl Med, 10, 1, 10.1186/1479-5876-10-1